All In Biotech

Drug Trial Radar · NCT04373785

NG101m Adjuvant Therapy in Glioblastoma Patients

A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients

Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Jul 30, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
NeuGATE TheranosticsIndustry
Sponsor type
Industry
First posted
May 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.

Conditions

  • Glioblastoma Multiforme

Interventions

  • Intensity-modulated radiation therapyRadiation

    Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.

  • TemozolomideDrug

    Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy. 1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles.

  • NG101mDrug

    Oral NG101m capsule continuously twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events and serious adverse eventsTime frame: 1 month
  2. Efficacy of NG101m adjuvant chemoradiation therapy assessed by measuring 2-year overall survival rate.Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yvonne Kew MD, PLLC

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.